Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene Therapy for Hemophilia.

Arthur W Nienhuis1, Amit C Nathwani2, Andrew M Davidoff3

  • 1Division of Experimental Hematology, Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|April 16, 2017
PubMed
Summary

Gene therapy using adeno-associated viral (AAV) vectors offers a potential cure for hemophilia A and B by enabling in vivo gene transfer. Clinical trials show promising therapeutic results, though immune responses remain a challenge.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rational engineering of the P5 TRS-mimic site and REP78/68 start codon yields promoter variants that improve rAAV purity while maintaining high titers.

Molecular therapy. Advances·2026
Same author

Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative.

Pediatric blood & cancer·2026
Same author

International Society of Paediatric Surgical Oncology (IPSO) Minimally Invasive Surgery (MIS) Guidelines.

Ecancermedicalscience·2026
Same author

Symptomatic Recurrent Splenomegaly Following Partial Splenectomy in Patients With Hereditary Spherocytosis.

Pediatric blood & cancer·2026
Same author

Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor.

Cell reports·2026
Same author

Capturing clinically actionable copy number alterations in Wilms tumor using nanopore sequencing.

Research square·2026

Area of Science:

  • * Hematology
  • * Gene Therapy
  • * Virology

Background:

  • * Hemophilia is a severe X-linked bleeding disorder requiring lifelong treatment with factor infusions.
  • * Current treatments for hemophilia A (factor VIII) and hemophilia B (factor IX) are burdensome and do not offer a cure.
  • * Gene therapy presents a potential curative approach for hemophilia.

Purpose of the Study:

  • * To review the clinical development of adeno-associated viral (AAV) gene transfer for hemophilia.
  • * To discuss the therapeutic and curative potential of in vivo gene therapy for hemophilia.
  • * To address challenges and future directions in AAV gene therapy for hemophilia.

Main Methods:

  • * In vivo gene transfer to the liver using adeno-associated viral (AAV) vectors.
Keywords:
clinical trialgene therapyhemophilia

Related Experiment Videos

  • * Clinical trial data analysis for therapeutic efficacy and safety.
  • * Investigation of cellular immune responses to AAV vectors.

    • Main Results:

    • * Successful therapeutic and potentially curative factor expression in human clinical trials.
    • * Demonstrated efficacy of AAV gene transfer in animal models.
    • * Identified cellular immune responses as a significant obstacle to sustained expression.

    Conclusions:

    • * AAV-mediated gene therapy has achieved a lasting cure for hemophilia in humans.
    • * Immune suppression protocols are being developed to manage anti-AAV immune responses.
    • * Continued research is essential for optimizing AAV gene therapy for hemophilia.